Current approaches and perspectives in human keratinocyte-based gene therapies

Gene Therapy

Volumn 11, Issue , 2004, Pages S57-S63

  Del Rio, M ^a   Gache, Y ^b   Jorcano, J L ^a   Meneguzzi, G ^b   Larcher, F ^a  

^a CIEMAT   (Spain)

^b INSERM   (France)

Author keywords

Gene transfer; Skin; Stem cells; Tissue engineering

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; COLLAGEN TYPE 7; COMPLEMENTARY DNA; ERYTHROPOIETIN; GROWTH HORMONE; INTERLEUKIN 10; INVOLUCRIN; KERATINOCYTE GROWTH FACTOR; LEPTIN; PLASMID DNA; SMALL INTERFERING RNA; VASCULOTROPIN;

CONTACT ALLERGY; DIABETES MELLITUS; DRUG SAFETY; DWARFISM; EPIDERMIS CELL; EPIDERMOLYSIS BULLOSA DYSTROPHICA; FOLLOW UP; GENE TARGETING; GENE TRANSFER; GENETIC MANIPULATION; HEMOPHILIA A; HUMAN; KERATINOCYTE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OBESITY; PRIORITY JOURNAL; REVIEW; SKIN CELL; SKIN DEFECT; SKIN ULCER; SOMATIC GENE THERAPY; SYSTEMIC DISEASE; VIRAL GENE DELIVERY SYSTEM; WOUND HEALING IMPAIRMENT;

ANIMALS; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC DISEASES, INBORN; HUMANS; KERATINOCYTES; MICE; MODELS, ANIMAL; SKIN DISEASES;

EID: 5444230652     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302370     Document Type: Review

References (49)

1. Spirito F, Meneguzzi G, Danos O, Mezzina M. Cutaneous gene transfer and therapy: the present and the future. J Gene Med 2001; 3: 21-31.
2. Gallico III GG et al. Permanent coverage of large burn wounds with autologous cultured human epithelium. N Engl J Med 1984; 311: 448-451.
3. Pellegrini G, Bondanza S, Guerra L, De Luca M. Cultivation of human keratinocyte stem cells: current and future clinical applications. Cell Eng 1998; 36: 1-13.
4. Llames SG et al. Human plasma as a dermal scaffold for the generation of a completely autologous bioengineered skin. Transplantation 2004; 77: 350-355.
5. Mathor MB et al. Clonal analysis of stably transduced human epidermal stem cells in culture. Proc Natl Acad Sci USA 1996; 93: 10371-10376.
6. Del Rio M et al. A preclinical model for the analysis of genetically modified human skin in vivo. Hum Gene Ther 2002; 13: 959-968.
7. Fenjves ES, Yao SN, Kurachi K, Taichman LB. Loss of expression of a retrovirus-transduced gene in human keratinocytes. J Invest Dermatol 1996; 106: 576-588.
8. Choate KA, Khavari PA. Sustainability of keratinocyte gene transfer and cell survival in vivo. Hum Gene Ther 1997; 8: 895-901.
9. Levy L et al. Optimized retroviral infection of human epidermal keratinocytes: long-term expression of transduced integrin gene following grafting on to SCID mice. Gene Therapy 1998; 5: 913-922.
10. Ortiz-Urda S et al. Stable nonviral genetic correction of inherited human skin disease. Nat Med 2002; 8: 1166-1170.
11. Chen M et al. Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa. Nat Genet 2002; 32: 670-675.
12. Hacein-Bey-Abina S et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science 2003; 302: 415-419.
13. Gache YG et al. Construction of skin equivalents for gene therapy of recessive dystrophic epidermolysis bullosa. Hum Gene Ther 2004 (in press).
14. Woodley DT et al. Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone. J Invest Dermatol 2003; 121: 1021-1028.
15. Ortiz-Urda S et al. Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue. J Clin Invest 2003; 111: 251-255.
16. Palazzi X et al. Inherited dystrophic epidermolysis bullosa in inbred dogs: a spontaneous animal model for somatic gene therapy. J Invest Dermatol 2000; 115: 135-137.
17. Baldeschi C et al. Genetic correction of canine dystrophic epidermolysis bullosa mediated by retroviral vectors. Hum Mol Genet 2003; 12: 1897-1905.
18. Morgan JR, Barrandon Y, Green H, Mulligan RC. Expression of an exogenous growth hormone gene by transplantable human epidermal cells. Science 1987; 237: 1476-1479.
19. Fenjves ES et al. Systemic distribution of apolipoprotein E secreted by grafts of epidermal keratinocytes: implications for epidermal function and gene therapy. Proc Natl Acad Sci USA 1989; 86: 8803-8807.
20. Gordon DA, Fenjves ES, Williams DL, Taichman LB. Synthesis and secretion of apolipoprotein E by cultured human keratinocytes. J Invest Dermatol 1989; 92: 96-99.
21. Teumer J, Lindahl A, Green H. Human growth hormone in the blood of athymic mice grafted withcultures of hormone-secreting human keratinocytes. FASEB J 1990; 4: 3245-3250.
22. Gerrard AJ, Hudson DL, Brownlee GG, Watt FM. Towards gene therapy for haemophilia B using primary human keratinocytes. Nat Genet 1993; 2: 180-183.
23. Meng X et al. Keratinocyte gene therapy for systemic diseases. Circulating interleukin 10 released from gene-transferred kera- tinocytes inhibits contact hypersensitivity at distant areas of the skin. J Clin Invest 1998; 101: 1462-1467.
24. Baek SC et al. Sustainable systemic delivery via a single injection of lentivirus into human skin tissue. Hum Gene Ther 2001; 12: 1551-1558.
25. Siprashvili Z, Khavari PA. Lentivectors for regulated and reversible cutaneous gene therapy. Mol Ther 2003; 9: 93-100.
26. Fakharzadeh SS, Zhang Y, Sarkar R, Kazazian HH. Correction of the coagulation defect in hemophilia A mice through factor VIII expression in skin. Blood 2000; 95: 2799-2805.
27. Larcher F et al. A cutaneous gene therapy approach to human leptin deficiencies: correction of the murine ob/ob phenotype using leptin-targeted keratinocyte grafts. FASEB J 2001; 15: 1529-1538.
28. Bellini MH, Peroni CN, Bartolini P. Increases in weight of growth hormone-deficient and immunodeficient (lit/scid) dwarf mice after grafting of hGH-secreting, primary human keratinocytes. FASEB J 2003; 17: 2322-2324.
29. Barrandon Y, Li V, Green H. New techniques for the grafting of cultured human epidermal cells onto athymic animals. J Invest Dermatol 1988; 91: 315-318.
30. Potten CS, Booth C. Keratinocyte stem cells: a commentary. J Invest Dermatol 2002; 119: 888-899.
31. Alonso L, Fuchs E. Stem cells of the skin epithelium. Proc Natl Acad Sci USA 2003; 100: 11830-11835.
32. Li A, Pouliot N, Redvers R, Kaur P. Extensive tissue-regenerative capacity of neonatal human keratinocyte stem cells and their progeny. J Clin Invest 2004; 113: 390-400.
33. Somani AK, Esmail N, Siminovitch KA. Gene therapy and dermatology: more than just skin deep. J Cutan Med Surg 1999; 5: 249-259.
34. Margolis DJ, Crombleholme T, Herlyn M. Clinical protocol: phase I trial to evaluate the safety of H5.020CMV.PDGF-B for the treatment of a diabetic insensate foot ulcer. Wound Repair Regen 2000; 8: 480-493.
35. Robbins PD, Evans CH. Prospects for treating autoimmune and inflammatory diseases by gene therapy. Gene Therapy 1996; 3: 187-189.
36. Marikovsky M et al. Appearance of heparin-binding EGF-like growth factor in wound fluid as a response to injury. Proc Natl Acad Sci USA 1993; 90: 3889-3893.
37. Brown LF et al. Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. J Exp Med 1992; 176: 1375-1379.
38. Eming SA et al. Genetically modified human keratinocytes overexpressing PDGF-A enhance the performance of a composite skin graft. Hum Gene Ther 1998; 9: 529-539.
39. Martin P. Wound healing - aiming for perfect skin regeneration. Science 1997; 276: 75-81.
40. Echtermeyer F et al. Delayed wound repair and impaired angiogenesis in mice lacking syndecan-4. J Clin Invest 2001; 107: R9-R14.
41. Del Rio M et al. Nonviral transfer of genes to pig primary keratinocytes. Induction of angiogenesis by composite grafts of modified keratinocytes overexpressing VEGF driven by a keratin promoter. Gene Therapy 1999; 6: 1734-1741.
42. Supp DM, Supp AP, Bell SM, Boyce ST. Enhanced vascularization of cultured skin substitutes genetically modified to overexpress vascular endothelial growth factor. J Invest Dermatol 2000; 114: 5-13.
43. Supp DM, Boyce ST. Overexpression of vascular endothelial growth factor accelerates early vascularization and improves healing of genetically modified cultured skin substitutes. J Burn Care Rehabil 2002; 23: 10-20.
44. ST Andreadis KE, Hamoen ML, Morgan JR. Keratinocyte growth factor induces hyperproliferation and delays differentiation in a skin equivalent model system. FASEB J 2001; 74: 898-906.
45. Hamoen KE, Morgan JR. Transient hyperproliferation of a transgenic human epidermis expressing hepatocyte growth factor. Cell Transplant 2002; 11: 385-395.
46. Romano Di Peppe S et al. Adenovirus-mediated VEGF(165) gene transfer enhances wound healing by promoting angiogenesis in CD1 diabetic mice. Gene Therapy 2002; 9: 1271-1277.
47. Serrano F et al. A comparison of targeting performance of oncoretroviral versus lentiviral vectors on human keratinocytes. Hum Gene Ther 2003; 14: 1579-1585.
48. Guenechea G, Gan OI, Dorrell C, Dick JE. Distinct classes of human stem cells that differ in proliferative and self-renewal potential. Nat Immunol 2001; 2: 75-82.
49. Mazurier F et al. Lentivector-mediated clonal tracking reveals intrinsic heterogeneity in the human hematopoietic stem cell compartment and culture-induced stem cell impairment. Blood 2004; 103: 545-552.